Copyright
©The Author(s) 2022.
World J Cardiol. Feb 26, 2022; 14(2): 96-107
Published online Feb 26, 2022. doi: 10.4330/wjc.v14.i2.96
Published online Feb 26, 2022. doi: 10.4330/wjc.v14.i2.96
Item | HR/OR (CI) |
PARIS-MB (HR) | |
Current smoking | 1.94 (1.18–3.20) |
CrCl < 60 mL/min | 1.81 (1.16–2.82) |
Age, per year increase | 1.02 (1.00–1.04) |
BMI | |
< 25 kg/m2 | 1.68 (1.09–2.60) |
≥ 35 kg/m2 | 1.79 (1.04—3.08) |
Anemia | 2.72 (1.83–4.04) |
Triple therapy on discharge | 1.93 (1.08–3.43) |
CRUSADE (HR) | |
Heart rate per 10 bpm increase | 1.08 (1.07–1.10) |
Systolic blood pressure | |
≤ 110 mmHg | 1.26 (1.16–1.36) |
≥ 180 mmHg | 1.24 (1.14–1.35) |
Hematocrit < 36% | 2.28 (2.11–2.46) |
CrCl, per 10 mL/min decrease | 1.12 (1.10–1.13) |
Sign of HF | 1.23 (1.15–1.31) |
Vascular disease | 1.19 (1.12–1.27) |
Diabetes | 1.16 (1.10–1.23) |
Female sex | 1.31 (1.23–1.39) |
ACUITY (OR) | |
Age, per 5 yr increase | 1.17 (1.13–1.21) |
Acute coronary syndrome | |
NSTEMI | 1.26 (1.04–1.54) |
STEMI | 1.92 (1.52–2.44) |
White blood cell count, giga/L | 1.10 (1.07–1.12) |
Serum creatinine, per 0.1 mg/dL increase | 1.09 (1.07–1.12) |
Anemia | 1.98 (1.65–2.37) |
Bivalirudin monotherapy | 0.56 (0.47–0.67) |
Female sex | 2.32 (1.98–2.72) |
HAS-BLED (OR) | |
Age > 65 yr | 2.66 (1.33-5.32) NS |
Systolic blood pressure >160 mmHg | 0.60 (0.21-1.72) NS |
Creatinine > 2.26 mg/dL or > 200 µmol/L or cirrhosis or bilirubin > 2 x normal with AST/ALT/AP > 3 x normal | 2.86 (1.33-6.18) |
Prior major bleeding or anemia | 7.51 (3.00-18.78) |
Medication predisposing to bleeding | 0.81 (0.43-1.51) NS |
Stroke | 0.94 (0.32-2.86) NS |
Labile INR | NR |
Alcohol use, ≥ 8 drinks/wk | 0.00 (0.00) NS |
PRECISE-DAPT (OR) | |
Hemoglobin, per 1 g increase | 0.67 (0.53-0.64) |
White-blood-cell count, per 103 cells per μL increase | 1.06 (0.99-1.13) |
Age, per 10 yr increase | 1.34 (1.11-1.48) |
CrCl, per 10 mL/min increase | 0.9 (0.82-0.99) |
Previous bleeding | 4.14 (1.22-14.02) |
- Citation: Persampieri S, Castini D, Lupi A, Guazzi M. Untangling the difficult interplay between ischemic and hemorrhagic risk: The role of risk scores. World J Cardiol 2022; 14(2): 96-107
- URL: https://www.wjgnet.com/1949-8462/full/v14/i2/96.htm
- DOI: https://dx.doi.org/10.4330/wjc.v14.i2.96